Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention
2011; Elsevier BV; Volume: 124; Issue: 3 Linguagem: Inglês
10.1016/j.ygyno.2011.11.024
ISSN1095-6859
AutoresLaia Alemany, Cristina Pérez, Sara Tous, Antonio Llombart‐Bosch, Belén Lloveras, Enrique Lerma, Rosa Guarch, Miguel Andújar, Adela Pelayo, María Alejo, Jaume Ordï, Joellen Klaustermeier, Julio Velasco, Núria Guimerà, Omar Clavero, Xavier Castellsagué, Wim Quint, Nubia Muñóz, F. Xavier Bosch, Silvia de Sanjosé,
Tópico(s)Infectious Diseases and Mycology
ResumoObjective Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. Methods 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF10 broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA25) (version 1). Results Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV 16, 18, 33, 31, 45, 35, 52 and 56, accounting for more than 90% of cases. HPV 16 and 18 contributed to 72.4% of all HPV positive ICC cases. In cervical adenocarcinomas, this contribution increased up to 94%. HPV 16 and 18 relative contributions showed a stable pattern over the 60 year study period. HPV 45, 18 and 16-positive ICC cases presented at younger ages than cases with other HPV types (adjusted mean age: 43.8, 45.2, 52.6 and 57.7 years, respectively). Conclusions HPV 16 and 18 accounted together for a 72.4% of positive cases, with no statistically significant changes in their relative contributions over the last decades. In 94% of cervical adenocarcinomas we identified at least one of the two HPV types included in the current vaccines (HPV 16/18). Results suggest a major impact of HPV vaccines on reduction of ICC burden in Spain in the HPV vaccinated cohorts.
Referência(s)